BioCentury
ARTICLE | Clinical News

Zebinix: Phase III data

September 26, 2016 7:00 AM UTC

Data from the PP population of 785 patients with newly diagnosed partial-onset seizures in a double-blind, Portuguese Phase III trial showed that once-daily oral Zebinix met the primary endpoint of non-inferiority to twice-daily carbamazepine CR in the proportion of patients with 26-week seizure freedom (71.1% vs. 75.6%). The non-inferiority margin was 12%. Zebinix was also non-inferior to carbamazepine CR in the proportion of seizure-free patients at 1 year (64.7% vs. 70.3%). Data were presented at the European Congress on Epileptology in Prague. ...